Abstract
Cystic fibrosis (CF) is the most common genetic disease in Caucasians that increases the mortality rate. This disease retards the passage of water and salt through the cells and therefore affects the vital functions of different organs. Pulmonary cystic fibrosis is the most common and responsible for the majority of symptoms, burden of care, and mortality. The gene that causes the disease has now been identified and sequenced. The lung diseases with CF are usually have three pathological elements; mucus obstruction, inflammation, and infection. In the last century, the relationship between CF, respiratory microbiology, and inflammation has been understood with increased longevity and development of new treatments and laboratory techniques. In this chapter, we will illustrate causes of CF lung diseases and modern therapeutic strategies.
Keywords
- cystic fibrosis
- pathogenic bacteria
- pneumonia infection
- pulmonary inflammation
- treatment guidelines
1. Introduction
Cystic fibrosis (CF) arises due to recessive mutations in the CF transmembrane regulator (CFTR) gene. This genetic disorder is carried out when two carrier parents transport the mutant CFTR gene to their child. Although no symptoms appear in the carriers, CF can be detected by genetic testing. CF-pulmonary diseases are usually associated with three pathological aspects; airway obstruction, infection, and inflammation. According to previous studies, children are most frequently infected by this disease with high rate of mortality.
The mutation that attacks CFTR gene leads to CF, and obstruction in the airways with abnormal mucus, infection, and inflammation is present. Although the current treatments cannot halt the disease progression, good nutrition, defective mucus clearance, and treatment of inflammation and infection greatly improve CF of the respiratory system and its complications [3]. There is a controversial relationship between infection and inflammation. Some scientists think that the infection should precede the inflammation of airways, while others suggest the opposite [4].
Americans and Europeans are more susceptible to CF. One in 29 people of Caucasian ancestry is a healthy carrier of the CF gene mutation [5]. Detection of CF in early phases is very useful due to symptom reduction, health improvement, and low cost. For example, since 2010s, all American newborns undergo screening for CF to provide a chance for recovery if the disease is diagnosed. Most patients of CF must take pancreatic enzymes to digest food effectively, and some require insulin for diabetes mellitus. The treatment cost of CF is very high because the drugs which treat and prevent the pulmonary diseases are very expensive [6]. Walaa et al. [7] report that 60 Egyptian children are affected by CF (6 months to 14 years). Salty skin is the most common symptom in the children affected with CF, because they suffer from dehydration due to loss of exuberant salty sweat. The percentage of ill males is 63%, while the percentage of ill females is 37%. Positive consanguinity of patients is 57%. 23% of patients has a positive family history of CF; the most frequent clinical presentation is pulmonary disease (84%), followed by pancreatic insufficiency (56%). The scientific material of this chapter aims to clearly interpret the roles of infection and inflammation in CF lung disease pathogenesis. Also, we will shed light on the therapeutic approaches to both infection and inflammation.
2. Microbes: CF interaction
2.1 Microbiology of CF lung disease
Severe and uncontrolled microbial infection may lead to CF. Microbes usually invade the airway luminal mucus, rather than tissues. Although
2.2 CF respiratory pathogens
2.2.1 Staphylococcus aureus
The two subtypes of
In some countries where CF lung disease is spreading, anti-staphylococcal agent is provided as a prophylaxis approach during childhood particularly when
2.2.2 Pseudomonas aeruginosa
After overcoming
Despite
Although
2.2.3 Burkholderia cepacia complex
2.2.4 Stenotrophomonas maltophilia
2.2.5 Haemophilus influenzae
2.2.6 Achromobacter xylosoxidans
2.2.7 Nontuberculous mycobacteria
Nontuberculous mycobacteria represent 6–30% of CF prevalence. Two groups of mycobacteria, accounting for six species, are currently considered important CF pathogens:
2.2.8 Fungi and viruses
A lot of fungi are isolated from CF patients, including yeasts such as
2.3 CF airway microbiome
Many studies which are concerned with identification of the microbiota of the respiratory system depend on DNA-sequencing techniques. The results of these techniques revealed that there is a wide diversity of microbiota inhabiting the respiratory system. This diversity of microbiota is high in young CF patients who have better lung functions and subsequently need fewer courses of antibiotics and vice versa in the case of adults. The most dominant microbiota in infected lungs of CF patients are
3. Immune response in CF lung disease
Destruction of the respiratory airways may carry out due to the chronic CF infections. This damage is mediated by abnormal response of the host to airway infections, which in turn leads to irreversible bronchiectasis and lung function decline [47]. Many studies report that, bacterial infection and inflammation are leading to triggering of neutrophils [48]. Moreover, the dysfunction of CF-CFTR is a main cause of altered immune defense and disorders in the airway’s environment. Appearance of neutrophil elastase (NE) is a good biomarker of disease [49].
The mutant CFTR gene leads to production of an abnormal protein, resulting in abnormal transport of salt and water across lining cells of the respiratory system, digestive system, and genital tracts. Insufficient water transport to the lining cells of the airways leads to formation of more thick and viscous respiratory secretions which clog small airways. Due to water reduction, the mucus becomes stagnant and infected with bacteria such as
The defective CF gene leads to defective CFTR and thick viscous secretions, which in turn lead to bronchial obstruction then to an infection then inflammation and finally bronchiectasis. Infection, inflammation, and bronchiectasis can lead to bronchial obstruction (Figure 1). Infection amplifies defective CF gene, which in turn leads to defective CFTR, which activates the resident airway inflammatory cells, which stimulate neutrophils and neutrophil products such as neutrophil elastase and monocytes, and finally bronchiectasis occurs (Figure 2).
The surface of epithelial lining cells of respiratory airways is dehydrated and acidified due to CFTR dysfunction, and abnormal mucociliary clearance is carried out. Dehydration is carried out due to water loss, while acidification is carried out due to bicarbonate loss [50, 51]. The neutrophilic inflammatory response is higher in CF than in non-CF patients. However, the neutrophilic inflammatory response is reduced in neutrophil apoptosis. Neutrophils and their products are accumulated due to deficiency in mucociliary clearance and macrophage dysfunction [52]. The passage airways may destruct by the action of anti-proteases, such as alpha-1-antitrypsin, a serine protease inhibitor, and secretory leukocyte protease inhibitor. So, neutrophil products such as proteases and elastases are released to react with anti-proteases and therefore avoid their deleterious action toward the passage airways [53, 54].
Some substances act as mediators of immune response and serve as important biomarkers of disease progression, such as neutrophil elastase, which is abundant in induced sputum in children with CF compared to control children [55]. High level of neutrophil elastase in induced sputum indicates lung dysfunctions and bronchiectasis [13]. The inflammation of the passage airways in sputum is reduced after detection and using of effective antibiotics for treatment of a CF-pulmonary diseases [56]. Inflammatory proteins are considered potential biomarkers of disease in CF. For example, the blood plasma proteins are biomarkers of CF disease [57].
The common example of immune response in CF lung disease is the immune response to
4. Anti-inflammatory therapy of CF
4.1 Ibuprofen
Ibuprofen inhibits neutrophil migration and aggregation [60]. It improves the lung functions especially in patients younger than 13 years. Gastrointestinal bleeding may be associated with chronic therapy. Recent studies report that high-dose ibuprofen could slow the progression of lung disease in CF, particularly in children with mild disease [61]. Despite the efficacy of ibuprofen for CF lung disease therapy, its use is uncommon compared to other CF therapies due to severe adverse effects such as kidney failure and gastric bleeding [62].
4.2 Azithromycin
Azithromycin is a broad-spectrum antibiotic belonging to macrolide group, and at the same time, it has immunomodulatory effects, so it has high effectiveness in the treatment of CF lung disease and other chronic inflammatory conditions [63]. Azithromycin may be used for a very long period (chronic azithromycin) either with or without chronic
4.3 Corticosteroids and leukotriene receptor antagonists
Corticosteroids, especially its systemic forms, or cortisones are powerful anti-inflammatory agents which are widely used in the treatment of CF. Although systemic corticosteroids can intensively improve lung functions, they have adverse effects that outweigh any benefit [67]. Inhaled corticosteroids do not have any efficacy in the treatment of CF [68]. Therefore, the treatment of CF by systemic or inhaled corticosteroids is not recommended by the Cystic Fibrosis (CF) Foundation [66]. On the other hand, leukotriene receptor antagonists (LTRAs) are nonsteroidal oral medications, which are used as anti-inflammatory bronchoconstriction preventors. LTRAs block a chemical reaction that leads to inflammation in the airways. LTRAs are effective as antihistamines, and they are better than placebo, but less effective than nasal corticosteroids in improving symptoms and quality of life in patients with seasonal allergic rhinitis [69].
5. Treatment management of CF
CF carrier testing is recommended for everybody especially for Caucasian women whether they are considering pregnancy or already pregnant. CF-carrier test must be made before marriage, because the marriage of the positive CF-carriers leads offspring affected with CF, and vice versa. So, the early diagnosis of CF either before birth or for newborns allows for earlier and faster treatment in CF centers and avoidance of serious complications including poor growth. CF centers must be accredited by the CF Foundation. CF centers have multidisciplinary teams of physicians, nurses, respiratory therapists, dietitians, and social workers who can care for both adult and pediatric patients [70]. Good nutrition for affected persons with CF increases lung functions and life expectancy. Once CF disease is diagnosed, the patient must follow a nutrition program that is including a high-calorie diet, pancreatic enzymes and a liberal-fat. Essential vitamins must be supplemented to reduce the risk of deficiency of certain fat-soluble vitamins.
Although ill infants and young children with CF have intermittent cough and wheezing, structural and functional abnormalities in the lung as early as the first few months of life are detected. CF treatments include physical methods to eliminate thick secretions from the chest. CF treatments with chemical methods include prescription of different medications, such as dornase alfa and hypertonic saline as thinners of sticky airway secretions, albuterol as bronchodilator, tobramycin as inhaled antibiotic, and ibuprofen and azithromycin as anti-inflammatory drugs [71]. Preventive measures against CF or its complications necessarily require frequent follow-up for nutrition, lung functions, and screening for complications in an accredited CF center.
6. Conclusion
CF lung disease is one of the many causes of morbidity and mortality worldwide. CF lung disease has indefinite symptoms including airway obstruction, infection, and inflammation. This disease is associated with different microorganisms such as
Acknowledgments
Authors sincerely thank National Organization for Drug Control and Research (NODCAR), Egypt, and Faculty of Science and Humanities, Shaqra University, Saudi Arabia for their support. Authors thank everybody aids in the introducing of this work as best as possible.
Notes
This chapter is concerned with CF-pulmonary diseases rather than other diseases of CF, because it is more widespread around the world and a common cause of morbidity and mortality especially in Caucasian areas as reported by the WHO.
References
- 1.
Andersen D. Cystic fibrosis of the pancreas and its relation to celiac disease: A clinical and pathological study. The American Journal of Diseases of Children. 1938; 56 :344-399. DOI: 10.1001/archpedi.1938.01980140114013 - 2.
Di Sant’agnese PEA, Andersen DH. Celiac syndrome; chemotherapy in infections of the respiratory tract associated with cystic fibrosis of the pancreas; observations with penicillin and drugs of the sulfonamide group, with special reference to penicillin aerosol. American Journal of Diseases of Children. 1946; 72 :17-61 - 3.
Lyczak JB, Cannon CL, Pier GB. Lung infections associated with cystic fibrosis. Clinical Microbiology Reviews. 2002; 15 :194-222. DOI: 10.1128/cmr.15.2.194-222.2002 - 4.
Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DW. Early pulmonary inflammation in infants with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine. 1995; 151 :1075-1082. DOI: 10.1164/ajrccm/151.4.1075 - 5.
O’Sullivan BP, Freedman SD. Cystic fibrosis. Lancet. 2009; 373 :1891-1904. DOI: 10.1016/S0140-6736(09)60327-5 - 6.
Ouyang L, Grosse SD, Amendah DD, Schechter MS. Healthcare expenditures for privately insured people with cystic fibrosis. Pediatric Pulmonology. 2009; 44 :989-996. DOI: 10.1002/ppul.21090 - 7.
Walaa AS, Dina AM, Mona ME. Mutation spectrum of Egyptian children with cystic fibrosis. Springerplus. 2016; 5 (686):1-6. DOI: 10.1186/s40064-016-2338-7 - 8.
Saiman L, Siegel JD, LiPuma JJ, Brown RF, Bryson EA, Chambers MJ, et al. Infection prevention and control guideline for cystic fibrosis: 2013 update. Infection Control and Hospital Epidemiology. 2014; 35 (Suppl 1):S1-S67. DOI: 10.1086/676882 - 9.
Worlitzsch D, Tarran R, Ulrich M, Schwab U, Cekici A, Meyer KC, et al. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. The Journal of Clinical Investigation. 2002;109 :317-325. DOI: 10.1172/JCI13870 - 10.
Singh PK, Schaefer AL, Parsek MR, Moninger TO, Welsh MJ, Greenberg EP. Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature. 2000; 407 :762-764. DOI: 10.1038/35037627 - 11.
Sagel SD, Ronald LG, Julia E, Sharon M, Jane LB, Jeffrey SW, et al. Impact of Pseudomonas andStaphylococcus infection on inflammation and clinical status in young children with cystic fibrosis. The Journal of Pediatrics. 2009;154 :183-188. DOI: 10.1016/j.jpeds.2008.08.001 - 12.
Gangell C, Gard S, Douglas T, Park J, de Klerk N, Keil T, et al. Inflammatory responses to individual microorganisms in the lungs of children with cystic fibrosis. Clinical Infectious Diseases. 2011; 53 :425-432. DOI: 10.1093/cid/cir399 - 13.
Pillarisetti N, Williamson E, Linnane B, Skoric B, Robertson CF, Robinson P, et al. Infection, inflammation, and lung function decline in infants with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine. 2011; 184 :75-81. DOI: 10.1164/rccm.201011-1892OC - 14.
Cogen J, Emerson J, Sanders DB, Ren C, Schechter MS, Gibson RL, et al. Risk factors for lung function decline in a large cohort of young cystic fibrosis patients. Pediatric Pulmonology. 2015; 50 :763-770. DOI: 10.1002/ppul.23217 - 15.
Hudson VL, Wielinski CL, Regelmann WE. Prognostic implications of initial oropharyngeal bacterial flora in patients with cystic fibrosis diagnosed before the age of two years. The Journal of Pediatrics. 1993; 122 :854-860. DOI: 10.1016/S0022-3476(09)90007-5 - 16.
Mayer-Hamblett N, Aitken ML, Accurso FJ, Kronmal RA, Konstan MW, Burns JL, et al. Association between pulmonary function and sputum biomarkers in cystic fibrosis. American Journal of Respiratory and Critical Care Medicine. 2007; 175 :822-828. DOI: 10.1164/rccm.200609-1354OC - 17.
Ahlgren HG, Andrea B, Jennifer SL, Joanie B, Elias M, Danuta R, et al. Clinical outcomes associated with Staphylococcus aureus andPseudomonas aeruginosa airway infections in adult cystic fibrosis patients. BMC Pulmonary Medicine. 2015;15 :67. DOI: 10.1186/s12890-015-0062-7 - 18.
Goss CH, Muhlebach MS. Review: Staphylococcus aureus and MRSA in cystic fibrosis. Journal of Cystic Fibrosis. 2011;10 :298-306. DOI: 10.1016/j.jcf.2011.06.002 - 19.
Hoffman LR, Déziel E, D'Argenio DA, Lépine F, Emerson J, McNamara S, et al. Selection for Staphylococcus aureus small-colony variants due to growth in the presence ofPseudomonas aeruginosa . Proceedings of the National Academy of Sciences of the United States of America. 2006;103 :19890-19895. DOI: 10.1073/pnas.0606756104 - 20.
Ren CL, Morgan WJ, Konstan MW, Schechter MS, Wagener JS, Fisher KA, et al. Presence of methicillin resistant Staphylococcus aureus in respiratory cultures from cystic fibrosis patients is associated with lower lung function. Pediatric Pulmonology. 2007;42 :513-518. DOI: 10.1002/ppul.20604 - 21.
Sawicki GS, Rasouliyan L, Pasta DJ, Regelmann WE, Wagener JS, Waltz DA, et al. The impact of incident methicillin resistant Staphylococcus aureus detection on pulmonary function in cystic fibrosis. Pediatric Pulmonology. 2008;43 :1117-1123. DOI: 10.1002/ppul.20914 - 22.
Muhlebach MS, Sonya LH, Elena BP, Melissa BM, Valeria T, Margaret K, et al. Multicenter observational study on factors and outcomes associated with different MRSA types in children with cystic fibrosis. Annals of the American Thoracic Society. 2015; 12 :864-871. DOI: 10.1513/AnnalsATS.201412-596OC - 23.
Dasenbrook EC, Merlo CA, Diener-West M, Lechtzin N, Boyle MP. Persistent methicillin-resistant Staphylococcus aureus and rate of FEV decline in cystic fibrosis. American Journal of Respiratory and Critical Care Medicine. 2008;178 :814-821. DOI: 10.1164/rccm.200802-327OC - 24.
Sanders DB, Bittner RC, Rosenfeld M, Hoffman LR, Redding GJ, Goss CH. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. American Journal of Respiratory and Critical Care Medicine. 2010; 182 :627-632. DOI: 10.1164/rccm.200909-1421OC - 25.
Dasenbrook EC, Checkley W, Merlo CA, Konstan MW, Lechtzin N, Boyle MP. Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis. Journal of the American Medical Association. 2010;303 :2386-2392. DOI: 10.1001/jama.2010.791 - 26.
Smyth AR, Walters S. Prophylactic anti-staphylococcal antibiotics for cystic fibrosis. Cochrane Database of Systematic Reviews. 2014; 11 :CD001912. DOI: 10.1002/14651858.CD001912.pub2 - 27.
Lo DKH, Hurley MN, Muhlebach MS, Smyth AR. Interventions for the eradication of methicillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis. Cochrane Database of Systematic Reviews. 2015;2 :CD009650. DOI: 10.1002/14651858.CD009650.pub2 - 28.
Gilligan PH. Microbiology of airway disease in patients with cystic fibrosis. Clinical Microbiology Reviews. 1991; 4 :35-51. DOI: 10.1128/cmr.4.1.35 - 29.
Langton-Hewer SC, Smyth AR. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database of Systematic Reviews. 2009;7 :CD004197. DOI: 10.1002/14651858.CD004197.pub3 - 30.
Regelmann WE, Elliott GR, Warwick WJ, Clawson CC. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. The American Review of Respiratory Disease. 1990;141 :914-921. DOI: 10.1164/ajrccm/141.4_Pt_1.914 - 31.
Mayer-Hamblett N, Kloster M, Rosenfeld M, Gibson RL, Retsch-Bogart GZ, Emerson J, et al. Impact of sustained eradication of new Pseudomonas aeruginosa infection on long-term outcomes in cystic fibrosis. Clinical Infectious Diseases. 2015;61 :707-715. DOI: 10.1093/cid/civ377 - 32.
Mayer-Hamblett N, Rosenfeld M, Gibson RL, Ramsey BW, Kulasekara HD, Retsch-Bogart GZ, et al. Pseudomonas aeruginosa in vitro phenotypes distinguish cystic fibrosis infection stages and outcomes. American Journal of Respiratory and Critical Care Medicine. 2014;190 :289-297. DOI: 10.1164/rccm.201404-0681OC - 33.
Li Z, Kosorok MR, Farrell PM, Laxova A, West SE, Green CG, et al. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. Journal of the American Medical Association. 2005;293 :581-588. DOI: 10.1001/jama.293.5.581 - 34.
Oliver A, Mulet X, Lõpez-Causapé C, Juan C. The increasing threat of Pseudomonas aeruginosa high-risk clones. Drug Resistance Updates. 2015;22 :41-59. DOI: 10.1016/j.drup.2015.08.002 - 35.
Mogayzel PJ, Naureckas ET, Robinson KA, Brady C, Guill M, Lahiri T, et al. Cystic fibrosis foundation pulmonary guideline. Pharmacologic approaches to prevention and eradication of initial Pseudomonas aeruginosa infection. Annals of the American Thoracic Society. 2014;11 :1640-1650. DOI: 10.1513/AnnalsATS.201404-166OC - 36.
Merlo CA, Boyle MP, Diener-West M, Marshall BC, Goss CH, Lechtzin N. Incidence and risk factors for multiple antibiotic-resistant Pseudomonas aeruginosa in cystic fibrosis. Chest. 2007;132 :562-568. DOI: 10.1378/chest.06-2888 - 37.
Zlosnik JEA, Zhou G, Brant R, Henry DA, Hird TJ, Mahenthiralingam E, et al. Burkholderia species infections in patients with cystic fibrosis in British Columbia, Canada. 30 years’ experience. Annals of the American Thoracic Society. 2015;12 :70-78. DOI: 10.1513/AnnalsATS.201408-395OC - 38.
Lipuma JJ. Update on the Burkholderia cepacia complex. Current Opinion in Pulmonary Medicine. 2005;11 :528-533. DOI: 10.1097/01.mcp.0000181475.85187.ed - 39.
Horsley A, Webb K, Bright-Thomas R, Govan J, Jones A. Can early Burkholderia cepacia complex infection in cystic fibrosis be eradicated with antibiotic therapy? Frontiers in Cellular and Infection Microbiology. 2011;1 :18. DOI: 10.3389/fcimb.2011.00018 - 40.
Regan KH, Bhatt J. Eradication therapy for Burkholderia cepacia complex in people with cystic fibrosis. Cochrane Database of Systematic Reviews. 2014;24 :CD009876. DOI: 10.1002/14651858.CD009876.pub2 - 41.
Avgeri SG, Matthaiou DK, Dimopoulos G, Grammatikos AP, Falagas ME. Therapeutic options for Burkholderia cepacia infections beyond co-trimoxazole: A systematic review of the clinical evidence. International Journal of Antimicrobial Agents. 2009;33 :394-404. DOI: 10.1016/j.ijantimicag.2008.09.010 - 42.
Parkins MD, Floto RA. Emerging bacterial pathogens and changing concepts of bacterial pathogenesis in cystic fibrosis. Journal of Cystic Fibrosis. 2015; 14 :293-304. DOI: 10.1016/j.jcf.2015.03.012 - 43.
Lipuma JJ. The changing microbial epidemiology in cystic fibrosis. Clinical Microbiology Reviews. 2010; 23 :299-323. DOI: 10.1128/CMR.00068-09 - 44.
Chmiel JF, Aksamit TR, Chotirmall SH, Dasenbrook EC, Elborn JS, LiPuma JJ, et al. Antibiotic management of lung infections in cystic fibrosis. I. the microbiome, methicillin-resistant Staphylococcus aureus , gram-negative bacteria, and multiple infections. Annals of the American Thoracic Society. 2014;11 :1120-1129. DOI: 10.1513/AnnalsATS.201402-050AS - 45.
Chmiel JF, Aksamit TR, Chotirmall SH, Dasenbrook EC, Elborn JS, LiPuma JJ, et al. Antibiotic management of lung infections in cystic fibrosis. II. Nontuberculous mycobacteria, anaerobic bacteria, and fungi. Annals of the American Thoracic Society. 2014; 11 :1298-1306. DOI: 10.1513/AnnalsATS.201405-203AS - 46.
Caverly LJ, Zhao J, LiPuma JJ. Cystic fibrosis lung microbiome: Opportunities to reconsider management of airway infection: Cystic fibrosis lung microbiome. Pediatric Pulmonology. 2015; 50 :S31-S38. DOI: 10.1002/ppul.23243 - 47.
Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. American Journal of Respiratory and Critical Care Medicine. 2003; 168 :918-951. DOI: 10.1164/rccm.200304-505SO - 48.
Muhlebach MS, Stewart PW, Leigh MW, Noah TL. Quantitation of inflammatory responses to bacteria in young cystic fibrosis and control patients. American Journal of Respiratory and Critical Care Medicine. 1999; 160 :186-191. DOI: 10.1164/ajrccm.160.1.9808096 - 49.
Noah TL, Black HR, Cheng PW, Wood RE, Leigh MW. Nasal and bronchoalveolar lavage fluid cytokines in early cystic fibrosis. The Journal of Infectious Diseases. 1997; 175 :638-647. DOI: 10.1093/infdis/175.3.638 - 50.
Boucher RC. Airway surface dehydration in cystic fibrosis: Pathogenesis and therapy. Annual Review of Medicine. 2007; 58 :157-170. DOI: 10.1146/annurev.med.58.071905.105316 - 51.
Pezzulo AA, Tang XX, Hoegger MJ, Abou Alaiwa MH, Ramachandran S, Moninger TO, et al. Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung. Nature. 2012; 487 :109-113. DOI: 10.1038/nature11130 - 52.
Alexis NE, Muhlebach MS, Peden DB, Noah TL. Attenuation of host defense function of lung phagocytes in young cystic fibrosis patients. Journal of Cystic Fibrosis. 2006; 5 :17-25. DOI: 10.1016/j.jcf.2005.11.001 - 53.
Birrer P, McElvaney NG, Rüdeberg A, Sommer CW, Liechti-Gallati S, Kraemer R, et al. Protease-antiprotease imbalance in the lungs of children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine. 1994; 150 :207-213. DOI: 10.1164/ajrccm.150.1.7912987 - 54.
Weldon S, McNally P, McElvaney NG, Elborn JS, McAuley DF, Wartelle J, et al. Decreased levels of secretory leucoprotease inhibitor in the Pseudomonas -infected cystic fibrosis lung are due to neutrophil elastase degradation. Journal of Immunology. 2009;183 :8148-8156. DOI: 10.4049/jimmunol.0901716 - 55.
Sagel SD, Kapsner R, Osberg I, Sontag MK, Accurso FJ. Airway inflammation in children with cystic fibrosis and healthy children assessed by sputum induction. American Journal of Respiratory and Critical Care Medicine. 2001; 164 :1425-1431. DOI: 10.1164/rccm2104075 - 56.
Ordonez CL, Henig NR, Mayer-Hamblett N, Accurso FJ, Burns JL, Chmiel JF, et al. Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis. American Journal of Respiratory and Critical Care Medicine. 2003; 168 :1471-1475. DOI: 10.1164/rccm.200306-731OC - 57.
Sagel SD, Thompson V, Chmiel JF, Montgomery GS, Nasr SZ, Perkett E, et al. Effect of treatment of cystic fibrosis pulmonary exacerbations on systemic inflammation. Annals of the American Thoracic Society. 2015; 12 :708-717. DOI: 10.1513/AnnalsATS.201410-493OC - 58.
Lovewell RR, Patankar YR, Berwin B. Mechanisms of phagocytosis and host clearance of Pseudomonas aeruginosa . American Journal of Physiology. Lung Cellular and Molecular Physiology. 2014;306 :L591-L603. DOI: 10.1152/ajplung.00335.2013 - 59.
Chattoraj SS, Murthy R, Ganesan S, Goldberg JB, Zhao Y, Hershenson MB, et al. Pseudomonas aeruginosa alginate promotesBurkholderia cenocepacia persistence in cystic fibrosis transmembrane conductance regulator knockout mice. Infection and Immunity. 2010;78 :984-993. DOI: 10.1128/IAI.01192-09 - 60.
Konstan MW, Vargo KM, Davis PB. Ibuprofen attenuates the inflammatory response to Pseudomonas aeruginosa in a rat model of chronic pulmonary infection. Implications for antiinflammatory therapy in cystic fibrosis. The American Review of Respiratory Disease. 1990;141 :186-192. DOI: 10.1164/ajrccm/141.1.186 - 61.
Lands LC, Stanojevic S. Oral non-steroidal anti-inflammatory drug therapy for lung disease in cystic fibrosis. Cochrane Database of Systematic Reviews. 2013; 6 :CD001505. DOI: 10.1002/14651858.CD001505.pub2 - 62.
Konstan MW, VanDevanter DR, Lawrence R, David JP, Ashley Y, Wayne JM, et al. Trends in the use of routine therapies in cystic fibrosis: 1995-2005. Pediatric Pulmonology. 2010; 45 :1167-1172. DOI: 10.1002/ppul.21315 - 63.
Zarogoulidis P, Papanas N, Kioumis I, Chatzaki E, Maltezos E, Zarogoulidis K. Macrolides: From in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases. European Journal of Clinical Pharmacology. 2012;68 :479-503. DOI: 10.1007/s00228-011-1161-x - 64.
Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa : A randomized controlled trial. Journal of the American Medical Association. 2003;290 :1749-1756. DOI: 10.1001/jama.290.13.1749 - 65.
Saiman L, Anstead M, Mayer-Hamblett N, Lands LC, Kloster M, Hocevar-Trnka J, et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa : A randomized controlled trial. Journal of the American Medical Association. 2010;303 :1707-1715. DOI: 10.1001/jama.2010.563 - 66.
Mogayzel PJ, Edward TN, Karen AR, Gary M, Denis H, Jeffrey BH, et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. American Journal of Respiratory and Critical Care Medicine. 2013; 187 :680-689. DOI: 10.1164/rccm.201207-1160OE - 67.
Eigen H, Rosenstein BJ, FitzSimmons S, Schidlow DV. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Cystic Fibrosis Foundation prednisone trial group. The Journal of Pediatrics. 1995; 126 :515-523. DOI: 10.1016/s0022-3476(95)70343-8 - 68.
Balfour-Lynn IM, Welch K. Inhaled corticosteroids for cystic fibrosis. Cochrane Database of Systematic Reviews. 2014; 10 :CD001915. DOI: 10.1002/14651858.CD001915.pub5 - 69.
Stelmach I, Korzeniewska A, Stelmach W, Majak P, Grzelewski T, Jerzynska J. Effects of montelukast treatment on clinical and inflammatory variables in patients with cystic fibrosis. Annals of Allergy, Asthma & Immunology. 2005; 95 :372-380. DOI: 10.1016/S1081-1206(10)61156-8 - 70.
Farrell PM, Rosenstein BJ, White TB, Accurso FJ, Castellani C, Cutting GR, et al. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. The Journal of Pediatrics. 2008; 153 :S4-S14. DOI: 10.1016/j.jpeds.2008.05.005 - 71.
Flume PA, O’Sullivan BP, Robinson KA, Goss CH, Mogayzel PJ Jr, Willey-Courand DB, et al. Cystic fibrosis pulmonary guidelines: Chronic medications for maintenance of lung health. American Journal of Respiratory and Critical Care Medicine. 2007; 176 :957-969. DOI: 10.1164/rccm.200705-664OC